| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3210936 | Journal of the American Academy of Dermatology | 2007 | 5 Pages |
Abstract
Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Akmal S. MD, Ursula MD, Lasse Roger MD, PhD, Nikhil MD,